A Phase 1, Open-Label, Dose-escalation Clinical Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) in Patients with Injectable Solid Tumors.

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-520258-39-00

Acronym

TILT-T115

Enrollment

Registered

2024-12-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

None listed

Sex/Gender

All

Age

18 Years to No maximum

Finland

None listed

Source: EU CTIS · Data processed: Feb 4, 2026